« Back
Home /
Daclizumab Biosimilar - Research Grade

Daclizumab Biosimilar - Research Grade

Manufacturer	IchorBio
Category	Antibodies In Vivo Antibodies
Type	Biosimilars
Specific against	Human
Isotype	IgG1
Applications	FA
Amount	20mg
Item no.	ICH5021-20MG
Targets	IL2RA
eClass 6.1	32160702
eClass 9.0	42030590
Available
Manufacturers Product Category	Low endotoxin, biosimilar antibody
Isotype Information	Human IgG1
Purification method	This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background	RUO daclizumab biosimilar is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
Concentration	5mg/ml
Formulation	Sterile, preservative-free, solution in PBS. BSA and Azide free.
Endotoxin	≤ 1.0 EU/mg as determined by the LAL method
Storage	This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Application Notes	This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use	Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 20mg

available

Delivery expected until 6/6/2024